CLINICAL_TRIALS
trial_result
· 2023-12-05
Clinical Trial Update: HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma [Phase 4]
Summary
Phase 4 trial updating HD IL-2 plus ipilimumab in metastatic melanoma has been terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Clinigen, Inc. | Conditions: Metastatic Melanoma | Phase 4 | Status: TERMINATED | Results posted: 2023-12-05